Scholtz & Company LLC Lowers Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Scholtz & Company LLC trimmed its holdings in Zoetis Inc. (NYSE:ZTS) by 3.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 23,867 shares of the company’s stock after selling 905 shares during the period. Zoetis accounts for approximately 1.8% of Scholtz & Company LLC’s holdings, making the stock its 23rd largest holding. Scholtz & Company LLC’s holdings in Zoetis were worth $4,138,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Webster Bank N. A. increased its position in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the last quarter. Private Wealth Management Group LLC acquired a new stake in shares of Zoetis during the 4th quarter worth $33,000. Neo Ivy Capital Management purchased a new position in shares of Zoetis in the 4th quarter worth $40,000. LRI Investments LLC acquired a new position in Zoetis in the first quarter valued at $43,000. Finally, Blue Bell Private Wealth Management LLC grew its position in Zoetis by 111.6% during the first quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock valued at $46,000 after acquiring an additional 144 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.4 %

NYSE:ZTS opened at $190.71 on Friday. The stock has a 50-day simple moving average of $182.52 and a 200 day simple moving average of $174.54. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The company has a market capitalization of $86.40 billion, a price-to-earnings ratio of 36.75, a price-to-earnings-growth ratio of 2.91 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.41 earnings per share. Sell-side analysts predict that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler upped their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. Finally, BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.